UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
  • TickerUCB
  • ISINBE0003739530
  • ExchangeEuronext Brussels
  • SectorPharmaceuticals & Biotechnology
  • CountryBelgium

Analysts

Alexander Makar ...
  • Cedric Duinslaeger
  • Guy Sips
  • Jan Opdecam
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs

Morning Note: AGFB BB, FLOB BB, GIMB BB, RET BB, UCB BB

Agfa: Röhrig (Active Ownership) Chairman of the Board Floridienne: 1Q19 trading update Gimv: Hands Benedenti back to its founders Retail Estates: FY18-19 results: strong top & bottom line UCB: Midazolam spray approved by US FDA

Martial Descoutures ...
  • Pierre Corby

UCB : Lack of visibility brings the margin under pressure

UCB is now entering a period of transition. Many challenges will have to be overcome including that of the patent cliff for Neupro (2021), Vimpat (2022) and Cimzia (2024), which together account for 66% of the group’s 2020e sales. It is our understanding that the challenges of 2019 and 2020 and the commercial success of Evenity (osteoporosis) and clinical success of bimekizumab (psoriasis) and rozanolixizumab (immunodeficiency) are putting pressure on margins in short term. With ...

Martial Descoutures ...
  • Pierre Corby

UCB : Un manque de visibilité qui induit une pression sur la marge

UCB entre dans une période de transition. De nombreux défis devront être surmontés dont celui de la chute brevetaire de Neupro (2021), Vimpat (2022) et Cimzia (2024) représentant à eux seuls 66% des ventes 2020e de la société. Aussi, nous comprenons tout l’enjeu de 2019 et 2020 et du succès commercial d’Evenity (ostéoporose) et clinique de bimekizumab (psoriasis) et rozanolixizumab (Immunodéficience) imposant une pression sur les marges à CT. Avec un PE 2020e de 14.2x conduisant ...

Martial Descoutures ...
  • Pierre Corby

UCB : Un manque de visibilité qui induit une pression sur la marge

UCB entre dans une période de transition. De nombreux défis devront être surmontés dont celui de la chute brevetaire de Neupro (2021), Vimpat (2022) et Cimzia (2024) représentant à eux seuls 66% des ventes 2020e de la société. Aussi, nous comprenons tout l’enjeu de 2019 et 2020 et du succès commercial d’Evenity (ostéoporose) et clinique de bimekizumab (psoriasis) et rozanolixizumab (Immunodéficience) imposant une pression sur les marges à CT. Avec un PE 2020e de 14.2x conduisant ...

Martial Descoutures ...
  • Pierre Corby

UCB : Lack of visibility brings the margin under pressure

UCB is now entering a period of transition. Many challenges will have to be overcome including that of the patent cliff for Neupro (2021), Vimpat (2022) and Cimzia (2024), which together account for 66% of the group’s 2020e sales. It is our understanding that the challenges of 2019 and 2020 and the commercial success of Evenity (osteoporosis) and clinical success of bimekizumab (psoriasis) and rozanolixizumab (immunodeficiency) are putting pressure on margins in short term. With ...

Alexander Makar ...
  • Cedric Duinslaeger
  • Guy Sips
  • Jan Opdecam
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs

Morning Note: AGFB BB, FLOB BB, GIMB BB, RET BB, UCB BB

Agfa: Röhrig (Active Ownership) Chairman of the Board Floridienne: 1Q19 trading update Gimv: Hands Benedenti back to its founders Retail Estates: FY18-19 results: strong top & bottom line UCB: Midazolam spray approved by US FDA

Martial Descoutures ...
  • Pierre Corby

UCB : Lack of visibility brings the margin under pressure

UCB is now entering a period of transition. Many challenges will have to be overcome including that of the patent cliff for Neupro (2021), Vimpat (2022) and Cimzia (2024), which together account for 66% of the group’s 2020e sales. It is our understanding that the challenges of 2019 and 2020 and the commercial success of Evenity (osteoporosis) and clinical success of bimekizumab (psoriasis) and rozanolixizumab (immunodeficiency) are putting pressure on margins in short term. With ...

Martial Descoutures ...
  • Pierre Corby

UCB : Un manque de visibilité qui induit une pression sur la marge

UCB entre dans une période de transition. De nombreux défis devront être surmontés dont celui de la chute brevetaire de Neupro (2021), Vimpat (2022) et Cimzia (2024) représentant à eux seuls 66% des ventes 2020e de la société. Aussi, nous comprenons tout l’enjeu de 2019 et 2020 et du succès commercial d’Evenity (ostéoporose) et clinique de bimekizumab (psoriasis) et rozanolixizumab (Immunodéficience) imposant une pression sur les marges à CT. Avec un PE 2020e de 14.2x conduisant ...

Martial Descoutures ...
  • Pierre Corby

UCB : Un manque de visibilité qui induit une pression sur la marge

UCB entre dans une période de transition. De nombreux défis devront être surmontés dont celui de la chute brevetaire de Neupro (2021), Vimpat (2022) et Cimzia (2024) représentant à eux seuls 66% des ventes 2020e de la société. Aussi, nous comprenons tout l’enjeu de 2019 et 2020 et du succès commercial d’Evenity (ostéoporose) et clinique de bimekizumab (psoriasis) et rozanolixizumab (Immunodéficience) imposant une pression sur les marges à CT. Avec un PE 2020e de 14.2x conduisant ...

Martial Descoutures ...
  • Pierre Corby

UCB : Lack of visibility brings the margin under pressure

UCB is now entering a period of transition. Many challenges will have to be overcome including that of the patent cliff for Neupro (2021), Vimpat (2022) and Cimzia (2024), which together account for 66% of the group’s 2020e sales. It is our understanding that the challenges of 2019 and 2020 and the commercial success of Evenity (osteoporosis) and clinical success of bimekizumab (psoriasis) and rozanolixizumab (immunodeficiency) are putting pressure on margins in short term. With ...

1 director sold

A director at Ucb SA sold 5,000 shares at 75.000EUR and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

Christophe Chaput ...
  • Emira Sagaama
  • Jerôme Bodin
  • Laurence Hofmann
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Philippe Ourpatian
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/28/2019

...

Christophe Chaput ...
  • Emira Sagaama
  • Jerôme Bodin
  • Laurence Hofmann
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Philippe Ourpatian
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 28/02/2019

...

Christophe Chaput ...
  • Johanna Jourdain
  • Laurence Hofmann
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 01/09/2019

...

Christophe Chaput ...
  • Johanna Jourdain
  • Laurence Hofmann
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 09/01/2019

...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/14/2018

...

UCB SA sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of UCB SA (BE), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date April 2, 2019, the closing price was EUR 77.80 and its potential was estimated at EUR 83.24.

Nurhayati Wan

UCB SA

Nurhayati Wan

UCB SA

Nurhayati Wan

UCB SA

Nurhayati Wan

UCB SA

ING
Hendrik Wiersma ...
  • Job Veenendaal
  • Nadège Tillier
  • Suvi Platerink Kosonen

Benelux Credit Digest/Issuer Profiles

Once again, it is with great pleasure that we present the eleventh edition of our Benelux Credit Digest, our annual overview of the key fundamentals and credit metric developments of the most important corporate and financial credits in Belgium, the Netherlands and Luxembourg.

Rahul Shah CFA ...
  • S.M Galibur Rahman

Bangladesh (IDLC): Banks – Asset quality issues shroud the promising story; we prefer BRAC Bank

We are cautious on the sector. On the back of the recent increase in non-performing loans outstanding, the sector’s systematic risk remains high. However, lower valuation (sector median 0.8x PB) suggests that this systematic risk is mostly priced in. Fundamentally, we expect moderate top-line growth and improved profitability for our coverage names. We use a dividend discount model to derive our target prices.

Expert Corporate Governance Service (ECGS)

UCB _ AGM and EGM 25 April 2019

In general, UCB is in compliance with the Belgian regulations relating to the organization and procedures of the Annual General Meeting. ITEMS 1 to 9 concern the Annual General Meeting. ITEMS E.1, E.2 and E.3 concern the Extraordinary Meeting. In the Ordinary General Meeting, in ITEM 5, the board of directors seeks approval of the Company's remuneration report. Since ECGS does not approve of long term incentive plans that do not operate one or more challenging performance conditions, we recommend to OPPOSE. Three re-elections are proposed: Ms. Evelyn du Monceau (ITEM 8.1), Mr. Cyril Jansse...

UCB– Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 27/04/2017

In general, UCB is in compliance with the Belgian regulations relating to the organization and procedures of the Annual General Meeting.Under ITEM 5, the Board of Directors seeks approval for the Company's remuneration report. Since we do not approve of LT incentive plans that do not operate one or more challenging performance conditions, we recommend opposition.Under ITEM 8.2a, the Nomination Committee proposes to re-elect Mr. Albrecht de Graeve. As we have concerns over his aggregate time commitments, we recommend opposition.Finally, under ITEM 9.1, the Board of Directors seeks authority to ...

Jérôme VINERIER

Short term view - UCB : The trend is bullish.

The trend is bullish. Prices are still making progress but the trend is slowing down. The next resistance is at €76.80. The break of €69.86 would endanger the trend.

Jérôme VINERIER

Analyse court terme - UCB : La tendance est haussière.

La tendance est haussière. Les cours progressent encore, mais la tendance s'affaiblit. La prochaine résistance est à 76,80 €. La rupture de 69,86 € mettrait la tendance en danger.

Jérôme VINERIER

Analyse court terme - UCB : La tendance est incertaine.

La tendance est incertaine. Les cours baissent, mais la tendance manque de puissance pour le moment. Le prochain support est à 69,86 €.

Jérôme VINERIER

Short term view - UCB : The trend is uncertain.

The trend is uncertain. Prices are falling, but the trend is lacking power for the time being. The next support is at €69.86.

Valérie GASTALDY

Medium term view - UCB : The correction is gaining traction.

The background trend is clearly bullish. The correction is gaining traction. It is too early to qualify this action as a bearish reversal. The trend would be invalidated below the support at €52.76.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch